+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Encephalopathy Market by Disease Type, Treatment Type, End-User, Severity, Age Group, Diagnosis Method, Application, Pathophysiology - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 180 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6015276
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Encephalopathy Market grew from USD 185.34 million in 2023 to USD 196.85 million in 2024. It is expected to continue growing at a CAGR of 6.15%, reaching USD 281.53 million by 2030.

Encephalopathy encompasses a broad spectrum of brain disorders characterized by altered mental status due to various causes, including infections, toxins, metabolic imbalances, and trauma. In the healthcare market, the necessity for early and accurate diagnosis of encephalopathy is escalating due to its severe impact on cognitive functions and quality of life. Applications span hospitals and clinics conducting advanced diagnostic imaging and laboratory tests to detect underlying causes. The end-use scope predominantly revolves around healthcare providers aiming to enhance patient outcomes through innovative treatment approaches and preventive measures. Key growth influencers in the encephalopathy market include the rising prevalence of neurological disorders, increased healthcare expenditure, advancements in diagnostic technologies, and a stronger focus on personalized medicine. As awareness about brain health increases, potential opportunities arise in integrating machine learning and AI into diagnostic processes for precision and speed. Collaborations between tech and healthcare companies to develop smarter diagnostic tools present untapped potentials. Meanwhile, limitations such as high costs associated with advanced diagnostic tools, limited awareness in emerging regions, and stringent regulatory requirements can impede market expansion. Additionally, the complexity of encephalopathy diagnosis due to its diverse etiologies remains a significant challenge. For innovation, areas such as the development of non-invasive diagnostic technologies, researching biomarkers for early detection, and exploring novel therapeutics targeting specific types of encephalopathy show promise. Insights into the market reveal a dynamic landscape influenced by technological advancements and a growing demand for integrated care solutions. Companies should focus on enhancing their R&D capabilities and forming strategic partnerships to navigate this evolving space. Encouraging investments in education and training programs on encephalopathy can strengthen market presence, particularly in regions with increasing healthcare demands. Overall, the encephalopathy market offers considerable growth opportunities conditioned on overcoming its inherent challenges.

Understanding Market Dynamics in the Encephalopathy Market

The Encephalopathy Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Development and availability of specialized diagnostic tools for accurate encephalopathy detection
    • The role of personalized medicine in tailoring treatment strategies for encephalopathy patients
    • Impact of chronic diseases such as diabetes and hypertension on encephalopathy prevalence and management
    • Integration of artificial intelligence in diagnosing and predicting the progression of neurological disorders
  • Market Restraints
    • High cost of treatment and diagnostics
  • Market Opportunities
    • Integrating artificial intelligence in diagnosing various forms of encephalopathy
    • Comprehensive patient education programs to improve encephalopathy treatment adherence
    • Developing telemedicine platforms for remote encephalopathy patient management
  • Market Challenges
    • Complexity of disease mechanisms and diagnosis

Exploring Porter’s Five Forces for the Encephalopathy Market

Porter’s Five Forces framework further strengthens the insights of the Encephalopathy Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Encephalopathy Market

External macro-environmental factors deeply influence the performance of the Encephalopathy Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Encephalopathy Market

The Encephalopathy Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Encephalopathy Market

The Encephalopathy Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Encephalopathy Market

The Encephalopathy Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Encephalopathy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., AstraZeneca PLC, Bayer AG, Biogen Inc, Boehringer Ingelheim International GmbH, Eisai Co., Ltd., Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Roche Holdings AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Encephalopathy Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Disease Type
    • Hepatic Encephalopathy
    • Hypertensive Encephalopathy
    • Toxic-Metabolic Encephalopathy
    • Traumatic Encephalopathy
    • Uremic Encephalopathy
    • Wernicke's Encephalopathy
  • Treatment Type
    • Medications
      • Antibiotics
      • Lactulose
      • Probiotics
      • Rifaximin
    • Surgery
      • Liver Transplantation
      • Neurosurgery
    • Therapies
      • Behavioral Therapy
      • Cognitive Rehabilitation
  • End-User
    • Ambulatory Surgical Centers
    • Hospitals
    • Research Institutes
    • Specialty Clinics
  • Severity
    • Acute Encephalopathy
    • Chronic Encephalopathy
    • Subacute Encephalopathy
  • Age Group
    • Adult
    • Geriatric
    • Pediatric
  • Diagnosis Method
    • Blood Tests
    • Electroencephalogram (EEG)
    • Imaging
      • CT Scan
      • MRI
      • Ultrasound
  • Application
    • Diagnostic
    • Research
    • Therapeutic
  • Pathophysiology
    • Anoxic Encephalopathy
    • Hypoxic Ischemic Encephalopathy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Development and availability of specialized diagnostic tools for accurate encephalopathy detection
5.1.1.2. The role of personalized medicine in tailoring treatment strategies for encephalopathy patients
5.1.1.3. Impact of chronic diseases such as diabetes and hypertension on encephalopathy prevalence and management
5.1.1.4. Integration of artificial intelligence in diagnosing and predicting the progression of neurological disorders
5.1.2. Restraints
5.1.2.1. High cost of treatment and diagnostics
5.1.3. Opportunities
5.1.3.1. Integrating artificial intelligence in diagnosing various forms of encephalopathy
5.1.3.2. Comprehensive patient education programs to improve encephalopathy treatment adherence
5.1.3.3. Developing telemedicine platforms for remote encephalopathy patient management
5.1.4. Challenges
5.1.4.1. Complexity of disease mechanisms and diagnosis
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Encephalopathy Market, by Disease Type
6.1. Introduction
6.2. Hepatic Encephalopathy
6.3. Hypertensive Encephalopathy
6.4. Toxic-Metabolic Encephalopathy
6.5. Traumatic Encephalopathy
6.6. Uremic Encephalopathy
6.7. Wernicke's Encephalopathy

7. Encephalopathy Market, by Treatment Type
7.1. Introduction
7.2. Medications
7.2.1. Antibiotics
7.2.2. Lactulose
7.2.3. Probiotics
7.2.4. Rifaximin
7.3. Surgery
7.3.1. Liver Transplantation
7.3.2. Neurosurgery
7.4. Therapies
7.4.1. Behavioral Therapy
7.4.2. Cognitive Rehabilitation

8. Encephalopathy Market, by End-User
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Hospitals
8.4. Research Institutes
8.5. Specialty Clinics

9. Encephalopathy Market, by Severity
9.1. Introduction
9.2. Acute Encephalopathy
9.3. Chronic Encephalopathy
9.4. Subacute Encephalopathy

10. Encephalopathy Market, by Age Group
10.1. Introduction
10.2. Adult
10.3. Geriatric
10.4. Pediatric

11. Encephalopathy Market, by Diagnosis Method
11.1. Introduction
11.2. Blood Tests
11.3. Electroencephalogram (EEG)
11.4. Imaging
11.4.1. CT Scan
11.4.2. MRI
11.4.3. Ultrasound

12. Encephalopathy Market, by Application
12.1. Introduction
12.2. Diagnostic
12.3. Research
12.4. Therapeutic

13. Encephalopathy Market, by Pathophysiology
13.1. Introduction
13.2. Anoxic Encephalopathy
13.3. Hypoxic Ischemic Encephalopathy

14. Americas Encephalopathy Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States

15. Asia-Pacific Encephalopathy Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam

16. Europe, Middle East & Africa Encephalopathy Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom

17. Competitive Landscape
17.1. Market Share Analysis, 2023
17.2. FPNV Positioning Matrix, 2023
17.3. Competitive Scenario Analysis
17.4. Strategy Analysis & Recommendation


List of Figures
FIGURE 1. ENCEPHALOPATHY MARKET RESEARCH PROCESS
FIGURE 2. ENCEPHALOPATHY MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ENCEPHALOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
FIGURE 15. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2023 VS 2030 (%)
FIGURE 17. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 19. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2023 VS 2030 (%)
FIGURE 21. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 25. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 27. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 30. ENCEPHALOPATHY MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 31. ENCEPHALOPATHY MARKET, FPNV POSITIONING MATRIX, 2023


List of Tables
TABLE 1. ENCEPHALOPATHY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ENCEPHALOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ENCEPHALOPATHY MARKET DYNAMICS
TABLE 7. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HYPERTENSIVE ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY TOXIC-METABOLIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY TRAUMATIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY UREMIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY WERNICKE'S ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY LACTULOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY RIFAXIMIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY LIVER TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY NEUROSURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY COGNITIVE REHABILITATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ACUTE ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY CHRONIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SUBACUTE ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ELECTROENCEPHALOGRAM (EEG), BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ANOXIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HYPOXIC ISCHEMIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 94. CANADA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 95. CANADA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 96. CANADA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 97. CANADA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 98. CANADA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 99. CANADA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. CANADA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 101. CANADA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 102. CANADA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 103. CANADA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 104. CANADA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. CANADA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 106. MEXICO ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 107. MEXICO ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 108. MEXICO ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 109. MEXICO ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 110. MEXICO ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 111. MEXICO ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. MEXICO ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 113. MEXICO ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 114. MEXICO ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 115. MEXICO ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 116. MEXICO ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. MEXICO ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 144. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 145. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 146. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 147. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 148. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 149. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 151. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 152. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 153. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 154. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 156. CHINA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 157. CHINA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 158. CHINA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 159. CHINA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 160. CHINA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 161. CHINA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 162. CHINA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 163. CHINA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 164. CHINA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 165. CHINA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 166. CHINA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. CHINA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 168. INDIA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 169. INDIA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 170. INDIA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 171. INDIA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 172. INDIA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 173. INDIA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. INDIA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 175. INDIA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 176. INDIA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 177. INDIA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 178. INDIA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. INDIA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 180. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 181. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 183. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 184. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 185. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 186. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 187. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 188. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 189. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 190. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 191. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 192. JAPAN ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 193. JAPAN ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 194. JAPAN ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 195. JAPAN ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 196. JAPAN ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 197. JAPAN ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 198. JAPAN ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 199. JAPAN ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 200. JAPAN ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 201. JAPAN ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 202. JAPAN ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. JAPAN ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 204. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 205. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 206. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 207. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 208. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 209. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 210. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 211. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 212. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 213. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 214. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 215. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 216. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 217. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 219. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 220. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 221. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 222. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 223. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 224. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 225. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 226. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 227. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 228. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 229. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 230. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 231. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 232. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 233. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 234. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 235. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 236. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 237. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 238. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 241. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 242. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 243. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 244. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 245. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 246. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 247. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 248. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 249. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 250. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 251. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 252. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 253. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 254. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 255. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 256. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 257. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 258. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 259. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 260. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 261. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 262. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 264. THAILAND ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 265. THAILAND ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 266. THAILAND ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 267. THAILAND ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 268. THAILAND ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 269. THAILAND ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 270. THAILAND ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 271. THAILAND ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 272. THAILAND ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 273. THAILAND ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 274. THAILAND ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 275. THAILAND ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 276. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 277. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 278. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 279. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 280. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 281. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 282. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 283. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 284. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 285. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 286. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 287. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 295. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 296. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 297. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 298. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 299. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 300. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 301. DENMARK ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 302. DENMARK ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 303. DENMARK ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 304. DENMARK ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 305. DENMARK ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 306. DENMARK ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 307. DENMARK ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 308. DENMARK ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 309. DENMARK ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 310. DENMARK ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 311. DENMARK ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 312. DENMARK ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 313. EGYPT ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 314. EGYPT ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 315. EGYPT ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 316. EGYPT ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 317. EGYPT ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 318. EGYPT ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 319. EGYPT ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 320. EGYPT ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 321. EGYPT ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 322. EGYPT ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 323. EGYPT ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 324. EGYPT ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 325. FINLAND ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 326. FINLAND ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 327. FINLAND ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 328. FINLAND ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 329. FINLAND ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 330. FINLAND ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 331. FINLAND ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 332. FINLAND ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 333. FINLAND ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 334. FINLAND ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 335. FINLAND ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 336. FINLAND ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 337. FRANCE ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 338. FRANCE ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 339. FRANCE ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 340. FRANCE ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 341. FRANCE ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 342. FRANCE ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 343. FRANCE ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 344. FRANCE ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 345. FRANCE ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 346. FRANCE ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 347. FRANCE ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 348. FRANCE ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 349. GERMANY ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 350. GERMANY ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 351. GERMANY ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 352. GERMANY ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 353. GERMANY ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 354. GERMANY ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 355. GERMANY ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 356. GERMANY ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 357. GERMANY ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 358. GERMANY ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 359. GERMANY ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 360. GERMANY ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
TABLE 361. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 362. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 363. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 364. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 365. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 366. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 367. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 368. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 369. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 370. ISRAEL ENCEPHALOPATH

Companies Mentioned

The leading players in the Encephalopathy Market, which are profiled in this report, include:
  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc
  • Boehringer Ingelheim International GmbH
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Roche Holdings AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

Methodology

Loading
LOADING...

Table Information